Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190,921 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress.
Okuda K, Umemura A, Kataoka S, Yano K, Takahashi A, Okishio S, Taketani H, Seko Y, Nishikawa T, Yamaguchi K, Moriguchi M, Nakagawa H, Liu Y, Mitsumoto Y, Kanbara Y, Shima T, Okanoue T, Itoh Y. Okuda K, et al. Among authors: liu y. Front Oncol. 2021 Nov 2;11:758549. doi: 10.3389/fonc.2021.758549. eCollection 2021. Front Oncol. 2021. PMID: 34796113 Free PMC article.
PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat.
Okishio S, Yamaguchi K, Ishiba H, Tochiki N, Yano K, Takahashi A, Kataoka S, Okuda K, Seko Y, Liu Y, Fujii H, Takahashi D, Ito Y, Kamon J, Umemura A, Moriguchi M, Yasui K, Okanoue T, Itoh Y. Okishio S, et al. Among authors: liu y. Sci Rep. 2020 Nov 11;10(1):19578. doi: 10.1038/s41598-020-75805-z. Sci Rep. 2020. PMID: 33177546 Free PMC article.
Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice.
Yano K, Yamaguchi K, Seko Y, Okishio S, Ishiba H, Tochiki N, Takahashi A, Kataoka S, Okuda K, Liu Y, Fujii H, Umemura A, Moriguchi M, Okanoue T, Itoh Y. Yano K, et al. Among authors: liu y. Lab Invest. 2022 Mar;102(3):281-289. doi: 10.1038/s41374-021-00680-9. Epub 2021 Nov 3. Lab Invest. 2022. PMID: 34732847 Free article.
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S, Xiong A, Yu J, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. Ren S, et al. Among authors: liu y. Cancer Immunol Immunother. 2024 May 10;73(7):124. doi: 10.1007/s00262-024-03715-4. Cancer Immunol Immunother. 2024. PMID: 38727837 Clinical Trial.
Pillararenes: a new frontier in antimicrobial therapy.
Jin Y, Liu Y, Zhu J, Liu H. Jin Y, et al. Among authors: liu y. Org Biomol Chem. 2024 May 10. doi: 10.1039/d4ob00396a. Online ahead of print. Org Biomol Chem. 2024. PMID: 38727528 Review.
190,921 results
You have reached the last available page of results. Please see the User Guide for more information.